Clicky

Evolus, Inc.(EOLS) News

Date Title
Mar 2 Is Evolus, Inc. (EOLS) the Best Small Cap Pharma Stock to Buy Now?
Feb 27 Evolus to Participate in Fireside Chats and One-on-One Meetings at Upcoming Investor Conferences
Feb 20 Evolus to Participate in the TD Cowen 2nd Annual Glowing Ahead: Beauty & Wellness Summit
Feb 18 Evolus to Report Fourth Quarter and Year End 2024 Results on March 4, 2025
Feb 14 Evolus (EOLS) Moves 5.5% Higher: Will This Strength Last?
Feb 13 Evolus Announces FDA Approval of Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels
Feb 10 With 70% ownership, Evolus, Inc. (NASDAQ:EOLS) boasts of strong institutional backing
Jan 22 Evolus (EOLS) Surges 28.3%: Is This an Indication of Further Gains?
Jan 21 Evolus, An AbbVie And Botox Rival, Just Hit The Stratosphere — Here's Why
Jan 21 Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Net Revenue, Achieving Record Results at the Top of the Company’s Guidance
Oct 10 Evolus' (NASDAQ:EOLS) investors will be pleased with their solid 119% return over the last three years
Oct 9 Evolus Inc (EOLS) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Advancements
Jul 30 Evolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in Australia
Jul 25 Evolus to Participate in the Canaccord Genuity 44th Annual Growth Conference
Jul 23 Evolus’s ‘frown line’ treatment Jeuveau could threaten Botox revenues
Jul 17 Evolus to Report Second Quarter Financial Results on July 31, 2024
Jun 24 Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for First Two Evolysse™ Dermal Filler Products
Jun 19 Market Sentiment Around Loss-Making Evolus, Inc. (NASDAQ:EOLS)
May 15 Evolus Celebrates Fifth Anniversary of Launching its Flagship Product Jeuveau® at the Women’s Wear Daily Beauty CEO Summit
May 10 Evolus’ Sandra Beaver Named Orange County Business Journal’s Public Company CFO of the Year